JP Morgan Chase
NRXP icon

JP Morgan Chase’s NRX Pharmaceuticals NRXP Stock Holding History

JP Morgan Chase’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$71 Hold
34
– – ﹤0.01% 7334
2025
Q4 		$92 Hold
34
– – ﹤0.01% 7221
2025
Q3 		$112 Hold
34
– – ﹤0.01% 7161
2025
Q2 		$111 Hold
34
– – ﹤0.01% 6826
2025
Q1 		$70 Sell
34
-19
-36% -$54 ﹤0.01% 6917
2024
Q4 		$117 Buy
53
+3
+6% +$4 ﹤0.01% 6988
2024
Q3 		$84 Buy
50
+16
+47% +$32 ﹤0.01% 7026
2024
Q2 		$83 Sell
34
-15
-31% -$53 ﹤0.01% 6923
2024
Q1 		$232 Sell
49
-1,632
-97% -$7.52K ﹤0.01% 6791
2023
Q4 		$7.73K Buy
1,681
+1,647
+4,844% +$5.44K ﹤0.01% 6472
2023
Q3 		$88 Hold
34
– – ﹤0.01% 6922
2023
Q2 		$164 Hold
34
– – ﹤0.01% 6650
2023
Q1 		$0 Hold
34
– – ﹤0.01% 7069
2022
Q4 		$0 Sell
34
-87,862
-100% -$885K ﹤0.01% 6848
2022
Q3 		$650K Buy
87,896
+87,701
+44,975% +$591K ﹤0.01% 4288
2022
Q2 		$1K Sell
195
-500
-72% -$6.57K ﹤0.01% 6369
2022
Q1 		$17K Buy
695
+177
+34% +$5.76K ﹤0.01% 6106
2021
Q4 		$25K Buy
518
+497
+2,367% +$35.9K ﹤0.01% 6162
2021
Q3 		$2K Buy
+21
New +$2.73K ﹤0.01% 6336

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

JP Morgan Chase's NRXP Position: Q1 2026 in Review

JP Morgan Chase held its NRX Pharmaceuticals (NRXP) position steady in Q1 2026 at 34 shares worth $71. The position accounts for ﹤0.01% of the portfolio, ranked #7334.

JP Morgan Chase first reported a position in NRXP in Q3 2021 and has held it in 19 quarters since. The position peaked at $650K in Q3 2022. 33 funds tracked by Wall St. Rank hold NRXP as of Q1 2026.

  • JP Morgan Chase held 34 shares of NRX Pharmaceuticals worth $71 as of Q1 2026.
  • JP Morgan Chase left its NRX Pharmaceuticals share count unchanged in Q1 2026.
  • NRX Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7334 holding.
  • JP Morgan Chase first reported a position in NRX Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • JP Morgan Chase's NRX Pharmaceuticals position peaked at $650K in Q3 2022.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.